Profile data is unavailable for this security.
About the company
Proteomics International Laboratories Ltd is an Australia-based medical technology company. The Company is engaged in predictive diagnostics and bio-analytical services. The Company specializes in proteomics, the study of the structure and function of proteins. The Company focuses on developing and commercializing diagnostic tests for chronic diseases. The Company operates in three business units unified by a technology platform: PromarkerD, Diagnostics and Analytical Services. The PromarkerD test system is a blood test that assess the risk of diabetic kidney disease (DKD) in patients with type 2 diabetes. Diagnostics includes Promarker platform, used to discover, verify, and analytically validate the panel of protein biomarkers for diabetic kidney disease. Its Analytical Services includes a proteomics-based technology platform, used to test, and validate the protein composition of varied range of products.
- Revenue in AUD (TTM)1.44m
- Net income in AUD-5.90m
- Incorporated2014
- Employees--
- LocationProteomics International Laboratories LtdHarry Perkins Institute, 6 Verdun StreetNEDLANDS 6009AustraliaAUS
- Phone+61 89389-1992
- Fax+61 86151-1038
- Websitehttps://www.proteomics.com.au/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Orthocell Ltd | 6.06m | -7.42m | 79.54m | -- | -- | 34.76 | -- | 13.13 | -0.0369 | -0.0369 | 0.0301 | 0.0109 | 0.2182 | 1.50 | 27.68 | -- | -26.73 | -32.67 | -31.96 | -38.53 | 77.11 | 63.04 | -122.55 | -374.46 | 4.36 | -- | 0.2586 | -- | 215.24 | 51.53 | 31.39 | -- | 11.07 | -- |
| Next Science Ltd | 34.14m | -25.04m | 91.88m | -- | -- | 4.66 | -- | 2.69 | -0.1082 | -0.1082 | 0.1458 | 0.0677 | 1.46 | 7.47 | 8.33 | -- | -107.19 | -74.40 | -136.06 | -90.31 | 73.20 | 76.98 | -73.36 | -128.26 | 3.45 | -50.37 | 0.0698 | -- | 89.36 | 50.80 | -28.29 | -- | -2.28 | -- |
| PharmAust Limited | 1.85m | -7.79m | 98.58m | 52.00 | -- | 12.53 | -- | 53.26 | -0.0236 | -0.0201 | 0.0055 | 0.02 | 0.1977 | -- | 6.71 | -- | -83.26 | -25.56 | -96.46 | -28.78 | 20.06 | 90.73 | -421.04 | -59.16 | -- | -104.65 | 0.00 | -- | -13.53 | 3.42 | -263.63 | -- | -47.47 | -- |
| Paradigm Biopharmaceuticals Ltd | 8.67m | -69.00m | 99.83m | -- | -- | 2.96 | -- | 11.52 | -0.2296 | -0.2296 | 0.0288 | 0.0962 | 0.1298 | -- | 2.25 | -- | -103.34 | -40.96 | -127.58 | -44.13 | 99.87 | -- | -796.30 | -466.85 | -- | -348.76 | 0.0085 | -- | 7.58 | 25.42 | -32.26 | -- | -- | -- |
| Vita Life Sciences Limited | 74.16m | 9.08m | 119.85m | 124.00 | 12.95 | 2.79 | 12.50 | 1.62 | 0.166 | 0.166 | 1.36 | 0.7695 | 1.33 | 2.34 | 7.35 | -- | 16.27 | 15.25 | 22.51 | 21.99 | 58.14 | 60.90 | 12.24 | 11.71 | 2.29 | -- | 0.0089 | 39.05 | 10.88 | 12.50 | 28.18 | 30.07 | 12.15 | 19.14 |
| Arovella Therapeutics Ltd | 139.02k | -10.23m | 120.77m | 14.00 | -- | 33.39 | -- | 868.71 | -0.0127 | -0.0127 | 0.0002 | 0.0034 | 0.0249 | -- | 15.15 | -- | -182.82 | -77.12 | -276.07 | -93.26 | 83.56 | 63.41 | -7,357.19 | -1,471.57 | -- | -- | 0.00 | -- | 45.47 | 0.3491 | -18.11 | -- | -68.72 | -- |
| Recce Pharmaceuticals Ltd | 6.81m | -11.32m | 139.71m | -- | -- | 261.21 | -- | 20.51 | -0.0637 | -0.0637 | 0.0385 | 0.0026 | 1.68 | -- | 52.84 | -- | -279.04 | -110.82 | -985.91 | -139.61 | -- | -- | -166.11 | -391.79 | -- | -24.07 | 0.2712 | -- | 39.53 | 27.79 | -19.03 | -- | -26.31 | -- |
| Proteomics International LaboratoriesLtd | 1.44m | -5.90m | 142.67m | -- | -- | 24.92 | -- | 98.74 | -0.0518 | -0.0518 | 0.0129 | 0.0437 | 0.1817 | -- | 11.13 | -- | -75.75 | -57.79 | -87.11 | -67.57 | -- | -- | -416.78 | -229.69 | -- | -283.47 | 0.0088 | -- | -14.64 | 4.12 | -24.20 | -- | 89.02 | -- |
| Dimerix Ltd | 181.28k | -10.87m | 184.11m | 0.00 | -- | 83.15 | -- | 1,015.63 | -0.0294 | -0.0294 | 0.0005 | 0.004 | 0.0169 | -- | 0.7586 | -- | -101.36 | -70.77 | -128.88 | -110.81 | -- | -- | -5,994.52 | -61,882.73 | -- | -- | 0.4541 | -- | 1,452.32 | 12.76 | -31.57 | -- | -8.26 | -- |
| Race Oncology Ltd | 885.59k | -11.17m | 213.98m | -- | -- | 10.32 | -- | 241.62 | -0.069 | -0.069 | 0.0055 | 0.125 | 0.0336 | -- | 0.326 | -- | -42.44 | -43.50 | -43.67 | -45.25 | -- | -- | -1,261.86 | -5,058.82 | -- | -- | 0.00 | -- | 997.63 | 93.78 | 11.41 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| FIL Investment Management (Hong Kong) Ltd.as of 25 Jan 2024 | 7.90m | 6.04% |
